ARS Pharmaceuticals, Inc. - 8-K Filing
ARS Pharmaceuticals appointed Donn Casale as CEO effective July 7, 2026, replacing Richard Lowenthal whose employment was terminated without cause the same day. Casale also joined the Board of Directors and will serve until the 2029 annual meeting. (Items: 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi)
Tickers: $SPRY